Literature DB >> 17670594

Prognostic value of the histological subtype in completely resected non-small cell lung cancer.

Tatsuro Okamoto1, Riichiroh Maruyama, Ryuichi Suemitsu, Yoshiro Aoki, Hiroshi Wataya, Miyako Kojo, Yukito Ichinose.   

Abstract

Non-small cell lung cancer (NSCLC), which includes several different histological subtypes, is usually treated by the same strategy. However, the biological behavior of each cell type appears to be different. We retrospectively reviewed the clinical records of 1119 consecutive NSCLC patients who underwent a complete resection, in order to investigate whether a histological cell type is a powerful prognostic factor. The overall 5- and 10-year survivals of the patients with adenocarcinoma (AD), squamous cell carcinoma (SQ), large cell carcinoma (LA), and adenosquamous cell carcinoma (AS) were 54.2 and 40.2%, 51.6 and 30.3%, 40.9 and 18.7%, and 35.1 and 30.1%, respectively. The AD patients had a significantly better survival than the non-AD patients in Stage I (P=0.0004), whereas the SQ patients had a better survival than the non-SQ patients in Stage II (P=0.018). A multivariate survival analysis indicated the AD patients to have a significantly better survival than the SQ patients in Stage IA (P=0.04), while the SQ patients had a better survival than the AD patients in Stage II (P=0.03). These above observations suggest that the prognosis after complete resection is different between adenocarcinoma and squamous cell carcinoma in Stage IA and II.

Entities:  

Year:  2006        PMID: 17670594     DOI: 10.1510/icvts.2005.125989

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  7 in total

1.  The two single nucleotide polymorphisms in the H37/RBM5 tumour suppressor gene at 3p21.3 correlated with different subtypes of non-small cell lung cancers.

Authors:  Juliana J Oh; Ashley K Koegel; Diana T Phan; Ali Razfar; Dennis J Slamon
Journal:  Lung Cancer       Date:  2007-07-02       Impact factor: 5.705

2.  TGFBI expression is an independent predictor of survival in adjuvant-treated lung squamous cell carcinoma patients.

Authors:  M J Pajares; J Agorreta; E Salvo; C Behrens; I I Wistuba; L M Montuenga; R Pio; A Rouzaut
Journal:  Br J Cancer       Date:  2014-01-30       Impact factor: 7.640

3.  Prognostic role of TPL2 in early‑stage non‑small cell lung cancer.

Authors:  Laura Boldrini; Mirella Giordano; Adele Servadio; Cristina Niccoli; Pietro Bertoglio; Marco Lucchi; Franca Melfi; Alfredo Mussi; Gabriella Fontanini
Journal:  Mol Med Rep       Date:  2017-04-03       Impact factor: 2.952

4.  Predicting recurrence using the clinical factors of patients with non-small cell lung cancer after curative resection.

Authors:  Hyun Joo Lee; Jisuk Jo; Dae-Soon Son; Jinseon Lee; Yong Soo Choi; Kwhanmien Kim; Young Mog Shim; Jhingook Kim
Journal:  J Korean Med Sci       Date:  2009-09-23       Impact factor: 2.153

5.  Transcriptional network classifiers.

Authors:  Hsun-Hsien Chang; Marco F Ramoni
Journal:  BMC Bioinformatics       Date:  2009-09-17       Impact factor: 3.169

6.  Centromere and kinetochore gene misexpression predicts cancer patient survival and response to radiotherapy and chemotherapy.

Authors:  Weiguo Zhang; Jian-Hua Mao; Wei Zhu; Anshu K Jain; Ke Liu; James B Brown; Gary H Karpen
Journal:  Nat Commun       Date:  2016-08-31       Impact factor: 14.919

7.  The Expression Levels of IL-4/IL-13/STAT6 Signaling Pathway Genes and SOCS3 Could Help to Differentiate the Histopathological Subtypes of Non-Small Cell Lung Carcinoma.

Authors:  Dorota Pastuszak-Lewandoska; Daria Domańska-Senderowska; Adam Antczak; Jacek Kordiak; Paweł Górski; Karolina H Czarnecka; Monika Migdalska-Sęk; Ewa Nawrot; Justyna M Kiszałkiewicz; Ewa Brzeziańska-Lasota
Journal:  Mol Diagn Ther       Date:  2018-10       Impact factor: 4.074

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.